Daniel Henderson - Concepedia

Author

Daniel Henderson

Royal Marsden NHS Foundation Trust ORCID

Also Known As

D R Henderson, D. Henderson, D.R. Henderson, Daniel Henderson, Daniel J Henderson, Daniel R Henderson, Daniel R. Henderson, Daniel Robert Henderson, Henderson, Daniel Robert

Publications

6.5K

Citations

H-Index

Concepts

All Affiliations

Royal Marsden NHS Foundation Trust Institute of Cancer Research University of Wisconsin–Madison SC Solutions (United States)Cardiff University

About

Daniel Henderson is an author at Royal Marsden NHS Foundation Trust specializing in medicine, radiation oncology, and urology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	15	18	2.5K
2	Health Sciences	3	3	550
3	Engineering	2	2	91
4	Education	1	1	15
5	Natural Sciences	1	1	193

Daniel Henderson

Publications

4.2K

Citations

H-Index

Page 1

	Year	Citations
Prostate attenuated replication competent adenovirus (ARCA) CN706: a selective cytotoxic for prostate-specific antigen-positive prostate cancer cells. Ronald Rodríguez, Eric R. Schuur, Ho Yeong Lim, PubMed Viral ReplicationSelective CytotoxicReplication Competent AdenovirusHuman Psa GeneMedicine	1997	590
Intensity-modulated fractionated radiotherapy versus stereotactic body radiotherapy for prostate cancer (PACE-B): acute toxicity findings from an international, randomised, open-label, phase 3, non-inferiority trial Douglas Brand, Alison Tree, Peter Ostler, The Lancet Oncology	2019	519
A phase I trial of CV706, a replication-competent, PSA selective oncolytic adenovirus, for the treatment of locally recurrent prostate cancer following radiation therapy. Theodore L. DeWeese, H. Van der Poel, S. Li, PubMed Translational MedicineUrologyRadiation MedicineCv706 AdministrationRadiation Therapy	2001	386
Prostate-specific Antigen Expression Is Regulated by an Upstream Enhancer Eric R. Schuur, Gail Henderson, Lena A. Kmetec, Journal of Biological Chemistry	1996	312
Progression-free Survival Following Stereotactic Body Radiotherapy for Oligometastatic Prostate Cancer Treatment-naive Recurrence: A Multi-institutional Analysis Piet Ost, Barbara Alicja Jereczek‐Fossa, Nicholas van As, European Urology Adaptive RadiotherapyUrologySurgical OncologyRadiation TherapyMedicine	2015	283
Intensity-modulated radiotherapy versus stereotactic body radiotherapy for prostate cancer (PACE-B): 2-year toxicity results from an open-label, randomised, phase 3, non-inferiority trial Alison Tree, Peter Ostler, H. van der Voet, The Lancet Oncology	2022	280
The addition of adenovirus type 5 region E3 enables calydon virus 787 to eliminate distant prostate tumor xenografts. D C Yu, Yu Chen, Michaela Su-Fern Seng, PubMed UrologyRegion E3Tail Vein InjectionMedicinePathology	1999	221
Identification of the transcriptional regulatory sequences of human kallikrein 2 and their use in the construction of calydon virus 764, an attenuated replication competent adenovirus for prostate cancer therapy. Dechao Yu, Gordon T. Sakamoto, Daniel Henderson PubMed Human Kallikrein 2Viral ReplicationGeneticsMolecular BiologyAdenovirus Type 5	1999	193
Antitumor synergy of CV787, a prostate cancer-specific adenovirus, and paclitaxel and docetaxel. Dechao Yu, Yu Chen, Jeanette Dilley, PubMed Tumor BiologyParticles Cv787MedicineProstate Cancer-specific AdenovirusPharmacology	2001	175
CV706, a prostate cancer-specific adenovirus variant, in combination with radiotherapy produces synergistic antitumor efficacy without increasing toxicity. Yu Chen, Theodore L. DeWeese, Jeanette Dilley, PubMed Synergistic Antitumor EfficacyRadiation MedicineCancer-associated VirusMedicineVirus Burst Size	2001	165

Page 1